Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03698331 · ClinicalTrials.gov registry record · Phase 4
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
A Phase 4 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT03698331: Completed Phase 4 study, sponsored by Neurocrine Biosciences.
NCT03698331 is a Phase 4 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03698331, a Phase 4 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
Primary Outcome
A withdrawal-emergent adverse event is an adverse event that begins during the Withdrawal Period.
Interventions
- DRUG Placebo oral capsule
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 4 |
What the finished NCT03698331 record still lists
NCT03698331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03698331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03698331 about?
NCT03698331 is a clinical study titled "The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine". This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
What is the current status of trial NCT03698331?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2018-09-14. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT03698331?
The interventions under investigation include: Placebo oral capsule (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT03698331?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03698331's enrollment target sits among peer trials
89 913th of 2000 higher than 1,085 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI